替米沙坦对老年不稳定型心绞痛患者内皮祖细胞数量及高敏C反应蛋白的影响  

Effect of Telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells in elder patients with unstable angina pectoris

作　　者：曹政[1] 余以勇 陈平英[1] 吴瑞霞[1] 陈彬[1] 华先平[1] 杨勇[1] 

机构地区：[1]湖北医药学院附属太和医院心内科,湖北十堰442000 [2]湖北省竹溪县人民医院心内科

出　　处：《临床心血管病杂志》2011年第11期834-837,共4页Journal of Clinical Cardiology

摘　　要：目的:观察替米沙坦对老年(年龄≥60岁)不稳定型心绞痛(UAP)患者外周血内皮祖细胞(EPCs)数量及高敏C反应蛋白(hs-CRP)的影响。方法:入选接受冠状动脉支架置入治疗(PCI)的老年UAP患者52例,随机分为替米沙坦组(PCI后加服替米沙坦80mg/d)和对照组(PCI后即刻加服安慰剂),PCI后即刻及4周后检测2组患者EPCs数量及hs-CRP水平的变化情况。结果:替米沙坦组与对照组PCI后即刻EPCs的数量基本相近;PCI 4周后2组EPCs数量均有所增加,但对照组与PCI后即刻比较差异无统计学意义。2组患者在PCI 4周后hs-CRP的水平均有明显的降低,但替米沙坦组降低的程度更为明显。结论:替米沙坦能够增加老年UAP患者EPCs的数量,显著降低其hs-CRP的水平,由此提示替米沙坦能够促进UAP患者EPCs的动员,有助于抑制机体的炎症反应,有助于改善老年UAP患者的预后。Objective：To evuluate whether telmisartan have the effect of the endothelial progenitor cell（EPCs） mobilizing and the anti-inflammatory function on elder patients with unstable angina pectoris（UAP）.Method：Fifty-two elder patients（age≥60 y） with UAP were randomized after successful percutaneous coronary intervention to Telmisartan 80 mg/d（27 patients） or placebo（25 patients）.Peripheral blood samples were drawn at baseline and at 4 weeks to assess the number of EPCs and to measure high-sensitivity C-reactive protein（hs-CRP）.Circulating EPCs were defined by the surface markers CD34＋/KDR＋ and analyzed by flow cytometry.Result：CD34＋/KDR＋ cells were similar at baseline.The number of EPCs were no significant change in the placebo group（[0.031±0.020]% vs [0.043±0.029]%,P0.05）.In contrast,a significant increase of the number of EPCs was seen in the Telmisartan group（[0.026±0.022]% vs [0.057±0.038]%,P0.05）.Hs-CRP levels,similar in the 2 groups at baseline,were significantly more decreased by Telmisartan than by placebo at follow up（P=0.023）.Conclusion：Telmisartan have the effect of EPCs mobilizing and a potent anti-inflammatory function in elder patients with UAP.

关 键 词：C反应蛋白 内皮祖细胞 替米沙坦 不稳定型心绞痛 老年 

分 类 号：Q51[生物学—生物化学]